Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SNS 01

Drug Profile

SNS 01

Alternative Names: SNS-01; SNS-01-T; SNS-101

Latest Information Update: 04 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Senesco Technologies
  • Developer Senesco Technologies; Sevion Therapeutics
  • Class Antineoplastics; Gene therapies; Small interfering RNA
  • Mechanism of Action Apoptosis stimulants; Cell adhesion molecule inhibitors; Eukaryotic initiation factor 5A modulators; NF-kappa B inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mantle-cell lymphoma; Multiple myeloma; Diffuse large B cell lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Bladder cancer; Diffuse large B cell lymphoma; Lung cancer; Mantle-cell lymphoma; Multiple myeloma

Most Recent Events

  • 17 Nov 2014 Suspended - Phase-I/II for Diffuse large B cell lymphoma (Second-line therapy or greater) in South Africa (IV)
  • 17 Nov 2014 Suspended - Phase-I/II for Diffuse large B cell lymphoma (Second-line therapy or greater) in USA (IV)
  • 17 Nov 2014 Suspended - Phase-I/II for Mantle cell lymphoma (Second-line therapy or greater) in South Africa (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top